Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC – A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)

Abstract

No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.